BSP – Biological Signal Processing Ltd. is a ground-breaking technological company, revolutionizing non-invasive diagnosis of cardiac disease.
The company was founded in 2000 by a team of seasoned researchers in the field of high frequency ECG analysis. Since then, it is devoted to advancing this subject – commercializing the technology to make it available to the medical community, creating a substantial clinical database and enhancing the knowledge base by promoting research activities.
BSP offers cutting-edge products with unmatched accuracy for non-invasive diagnosis and monitoring of Ischemic Heart Disease. The HyperQ™ line of products, which is based on the patented high frequency technology, offers solutions for both Stress ECG tests and Resting ECG tests. The HyperQ stress offers a significant improvement in the diagnostic process of patients suspected of having Coronary Artery Disease. The HyperQ Rest provides a revolutionary tool for Emergency Department teams in detecting Acute Coronary Syndrome.
Numerous trials and clinical studies in Israel, Europe, Asia and the US, on thousands of patients, have confirmed the significantly enhanced diagnostic value of the HyperQ technology for the detection of Ischemia.
BSP has been publicly traded on the Tel Aviv Stock Exchange since 2006. Its headquarters are located in Tel Aviv, Israel.